Table 1.

The clinicopathologic features of the 8 xenograft donor patients

MDA PCa cell line designationa
Feature79117130144146155170180
At presentation
 Age (y)6160656874726372
 PSA (ng/mL)6599244.610.71.719.853
 NBx morphologyAdCaAdCaAdCaAdCaAdCaSCCAdCaAdCa
 Gleason score4 + 45 + 54 + 44 + 33 + 499
Prior treatment
 Androgen ablationYesYesYesYesYesYesYesYes
 RadiationYesNoYesYesYesNoNoNo
 ChemotherapyYesYesYesYesYesYesYesYes
At surgery
 Age (y)6764767278726474
 ProcedurePECPXCPXPECPXPECPXCPX
 Tissue morphologyAdCaAdCa with NE diffAdCaMixed AdCa SCPC and LCNECMixed AdCa and SCPCSCPCAdCaAdCa
 Gleason score5 + 44 + 54 + 54 + 45 + 45 + 45 + 4
 Pathologic stageT4NxT4N1T4N0T4N1T4N1T4N0T4N1T4N1
Overall survival (y)13.35.317.64.86.20.62.53.8
Site of tissue collectionRE–1b PRPR–4 PR–10 BL–2 BL–1 PR–11 BL
–9 PR–6 PR–12b BL–9 BL–4 PR–14 BL
–9 PR–17 BL–12 BL− 18 BL
–11 BL–20 BL–16 PR− 21 BL
–13 BL−30 SV
–17 BL
–20 RE
–23 RE

Abbreviations: PSA, prostate-specific antigen; NBx, needle biopsy; AdCa, adenocarcinoma; SCC, small-cell carcinoma; PE, pelvic exenteration; CPX, cystoprostatectomy; NE diff, neuroendocrine differentiation; SCPC, small-cell prostate carcinoma; LCNEC, large-cell NE carcinoma; RE, rectal wall; PR, prostate; BL, bladder wall; SV, seminal vesicles.

  • aNumbers indicated by “–” are cell sublines.

  • bThese xenografts were unstable and were not developed any further.